Primary Versus Severe IGF-1 Deficiency @checkrare
Primary Versus Severe IGF-1 Deficiency  @checkrare
Uploaded July 2026 | Updated November 2026, 2 hours ago
Robert Rapaport, MD, Professor of Pediatric Endocrinology, and Director of the Comprehensive Growth Center at the Icahn School of Medicine, Mount Sinai Medical Center, New York City, discussed the differences between severe, primary IGF-1 deficiency and growth hormone (GH) deficiency in patients with short stature.

In young patients with short stature, GH deficiency is the most common cause. However, in a small subset of patients, the underlying problem is not GH deficiency but an abnormality in insulin-like growth factor-1 (IGF-1) levels. This peptide hormone was first discovered 50 years ago, and IGF-1 deficiency has been found to be caused by mutations in the GH receptor and defects in the IGF-1 gene. In patients with a specific subtype of severe, primary IGF-1 deficiency (SPIGF1D) called Laron syndrome, the specific cause is GH-receptor mutations.

Severe, primary IGF-1 deficiency is generally associated with the following patient characteristics: severe postnatal growth failure, short limb length, typical facial features (e.g., small forehead), and delays in sexual development and skeletal maturation. Crucially, affected children do not respond to a GH stimulation test.

Patients who have abnormally low GH levels can also be considered IGF-1 deficient. On the other hand, if the patient has normal GH levels, IGF-1 concentrations may still be abnormally low. According to Dr. Rapaport, patients with IGF-1 deficiency may be found to have abnormal IGF-1 levels across a spectrum from borderline low to extremely low, the latter of which represents the main feature of SPIGF1D (IGF-1 levels are 5–6 standard deviations below the mean for healthy individuals).

The only effective treatment for SPIGF1D is IGF-1 supplementation, with mecasermin, a human recombinant IGF-1 preparation. Although mecasermin is proven to increase patients’ growth velocity, patients taking the product are expected to attain “near normal” adult height only. It is given twice daily, and it does carry a risk of hypoglycemia, as IGF-1 lowers blood glucose levels. It is thus important that patients and their caregivers are well educated about avoiding this dangerous adverse effect.
Primary Versus Severe IGF-1 DeficiencyHighlights from The Liver Meeting 2026Fabry Disease: How Well Does Your Medical Team Work Together and Understand Fabry Disease?Increased Dosing Interval of Mogamulizumab in Patients With CTCLThe Changing Myasthenia Gravis Treatment LandscapePatient Perspective: Diagnostic Journey With IgA NephropathyC3G and the Pediatric VALIANT StudyIMAAVY Approval for wAIHAFDA Approves Multiple Myeloma Drug;  FDA Denies Neuroendocrine Drug; Safety Concerns For Prader-W...FDA Approves Rare Disease Treatments as Huntington’s Gene Therapy AdvancesNew Rare Disease Center of Excellence and FDA Advances in Rare DiseaseEXPAND Study on Ultra-Rare Cholestatic Liver Disease
CheckRare |

Primary Versus Severe IGF-1 Deficiency

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER